ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607)

Recombinant human monoclonal antibody to Cannabinoid Receptor I for ELISA, FACS, Functional Assay and In Vivo.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 12-18 business days.
Name
Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free
Description
Recombinant human monoclonal antibody to Cannabinoid Receptor I.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivity
Human, Cynomolgus Macaque
Host
Human
Clonality
Monoclonal
Isotype
IgG4
Light Chains
kappa
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Molecular Weight
This antibody has a predicted MW of 145 kDa.
Purity
> 95% (by SDS-PAGE and SEC-HPLC).
Product Form
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Synonyms
CANN6, Cannabinoid receptor 1, CB-R, CB1, CNR, CNR1
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607)? Please let us know so that we can list the citation on this page.

Alternative products to Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607)

Proteins predicted to interact with Cannabinoid Receptor I

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
99.5% Relevancy Score
99.3% Relevancy Score
99% Relevancy Score
98.3% Relevancy Score
97.2% Relevancy Score
94.3% Relevancy Score